Online programme to help diabetes patients
pharmafile | September 14, 2012 | News story | Medical Communications, Sales and Marketing | Boehringer, diabetes, lilly
Boehringer Ingelheim and Eli Lilly have launched an online initiative which they say will help diabetes sufferers make simple lifestyle changes to manage their condition.
The so-called ‘beyond pill’ programme is designed to help patients set small goals in areas such as better eating and taking exercise, which will in turn – at least this is the idea – lead to them making even more significant changes in time.
People with type 2 diabetes can register for free and create their own My Well Planner account at www.mywellplannerinfo.com and then take a self-assessment to see how motivated they are.
This allows goals to be personalised – breaking old habits and creating new ones – with progress reports which patients can print out and take to their doctor to discuss during appointments.
While medication is important in treating type 2 diabetes, healthy diet and exercise are also key when it comes to successfully controlling blood glucose levels.
“There is no one-size-fits-all approach to managing type 2 diabetes,” said David Pass, vice president, metabolism marketing, Boehringer.
The combination of online activity and treatment is an obvious one that is being tapped into increasingly by health authorities keen to take pressure off existing services by encouraging self-help.
An estimated 366 million people have diabetes, with type 2 accounting for up to 95% of all cases – and that number is set to grow as more people live sedentary lifestyles and eat unhealthily.
It is also a good fit for the companies: Boehringer and Lilly co-market diabetes treatments Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin hydrochloride) tablets.
About 25.8 million Americans – 8.3% of the population – have diabetes at present and the Centers for Disease Control and Prevention projects that one in three US adults could have diabetes by 2050, if current trends continue.
Adam Hill
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
